Iga Swiatek, the world No. 2 tennis player, has accepted a one-month suspension after testing positive for banned substance trimetazidine. The International Tennis Integrity Agency ruled that the positive test was unintentional and due to contamination from melatonin, a nonprescription medication she used for jet lag. Swiatek's suspension commenced after she missed three tournaments earlier. In total, she forfeits prize money from her Cincinnati Open performance as part of her penalty. The case highlights ongoing challenges athletes face regarding medication safety in competitive environments.